Sugi Predict

Sugi Predict / Compounds / SCHEMBL31040798

SCHEMBL31040798

SCHEMBL31040798

COC(=O)c1ccc2nc(N)c3cncn3c2n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LCK P06239 3/20 0.37
▸ MAPK1 P28482 1/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ DAPK3 O43293 1/20 0.35
▸ JAK2 O60674 1/20 0.35
▸ PRKD3 O94806 1/20 0.35
▸ MAP4K4 O95819 1/20 0.35
▸ ABL1 P00519 1/20 0.35
▸ CSF1R P07333 1/20 0.35
▸ RET P07949 1/20 0.35
▸ MET P08581 1/20 0.35
▸ PDGFRA P16234 1/20 0.35
▸ PRKACA P17612 1/20 0.35
▸ LTK P29376 1/20 0.35
▸ GRK5 P34947 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ MAPK8 P45983 1/20 0.35
▸ MAPK9 P45984 1/20 0.35
▸ CSNK1A1 P48729 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31040789 0.86 MAPT (0.44) LCKMAPK1KDM4EALDH1A1HPGD
SCHEMBL31040788 0.85 BTK (0.41) LCKMAPK1KDM4EALDH1A1HPGD
SCHEMBL31026828 0.84 CHEK1 (0.34) LCKKDM4EALDH1A1HPGDTSHR
SCHEMBL31137728 0.78 LCK (0.58) LCKKDM4EALDH1A1HPGDHSD17B10
SCHEMBL31040759 0.75 CDK5 (0.40) KDM4EALDH1A1CDK5GAAMAPT
SCHEMBL31136583 0.72 LCK (0.45) LCKKDM4EALDH1A1HPGDHSD17B10
SCHEMBL31040851 0.71 LCK (0.44) LCKKDM4EALDH1A1HPGDTSHR
SCHEMBL31137636 0.71 LCK (0.38) LCKKDM4EALDH1A1HPGDTSHR
SCHEMBL31137152 0.71 ILK (0.41) LCKKDM4EALDH1A1ABL1HPGD
SCHEMBL24174887 0.67 MAPK1 (0.42) MAPK1KDM4EALDH1A1DYRK1APTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122070134-A Use of PRMT5 inhibitors in the treatment of tumors or cancers 上海湃隆生物科技有限公司 2026-05-19 — — CN disclosed
US-20260125380-A1 PRMT5 INHIBITORS AND METHODS OF USE SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2026-05-07 — — US disclosed
EP-4592289-A1 NOVEL PRMT5 INHIBITOR AND USE THEREOF Shanghai Apeiron Therapeutics Company Limited (CN) 2025-07-30 — — EP disclosed
US-20250051331-A1 PRMT5 INHIBITORS AND METHODS OF USE SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2025-02-13 — — US disclosed
US-12173002-B2 PRMT5 inhibitors and methods of use SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2024-12-24 — — US disclosed
US-20240294528-A1 PRMT5 INHIBITORS AND METHODS OF USE SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2024-09-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12173002-B2 PRMT5 inhibitors and methods of use PRMT5, PRMT1, PRMT7 LCK 1443/4885MAPK1 1413/4885KDM4E 115/4885
US-20250051331-A1 PRMT5 INHIBITORS AND METHODS OF USE PRMT5, PRMT1, PRMT7 LCK 1052/4885MAPK1 493/4885KDM4E 85/4885
US-20260125380-A1 PRMT5 INHIBITORS AND METHODS OF USE PRMT1, PRMT5, PRMT6 LCK 977/4885MAPK1 733/4885KDM4E 40/4885
US-20240294528-A1 PRMT5 INHIBITORS AND METHODS OF USE PRMT5, PRMT1, PRMT3 LCK 1157/4885MAPK1 1232/4885KDM4E 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.